Ischaemic Heart Disease Clinical Trial
— Integration-IIOfficial title:
Impact of Real-time Angiographic Co-registered OCT on PCI Results - the Randomized OPTICO-integration II Study
Verified date | April 2019 |
Source | Charite University, Berlin, Germany |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Intracoronary optical coherence tomography (OCT) imaging allows for high-resolution characterization of coronary lesions. Difficulties in matching cross-sectional OCT-images with angiographic lesion localization, however, may limit its clinical utilization. The investigators sought to prospectively assess the impact of a novel system of real-time OCT-coregistration with angiography (ACR) compared to OCT alone and to the clinical standard proceeding (angiographic guided-PCI) all used for coronary lesion evaluation before percutaneous coronary interventions (PCI). The investigators hypothesize that the use of ACR will lead to less incidence of insufficient covered coronary lesions (geographical mismatch) and/or a less rate of edge dissections after PCI (combined primary study endpoint)
Status | Completed |
Enrollment | 84 |
Est. completion date | March 15, 2019 |
Est. primary completion date | November 29, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Patient with indication for coronary angiography for angina (stable or unstable), silent ischemia (a visually estimated target lesion diameter stenosis of =70%, a positive invasive or non-invasive test must be present), or NSTE-ACS - male or non pregnant female patient - Signed written informed consent Exclusion Criteria: - Known neoplasia on treatment / without a curative therapeutic approach - Presence of one or more co-morbidities which reduces life expectancy to less than 24 months - Estimated creatinine clearance <40 ml/min - Cardiogenic shock - Hemodynamic instability because of arrhythmia - Known left ventricular ejection fraction (LVEF) <30%. - Therapy requiring psychiatric disorder - Patient is participating in any other investigational drug or device clinical trial that has not reached its primary endpoint. - Women who are pregnant or breastfeeding - Refusal of study participation |
Country | Name | City | State |
---|---|---|---|
Germany | Charité - Universitätsmedizin Berlin | Berlin |
Lead Sponsor | Collaborator |
---|---|
Charite University, Berlin, Germany |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of a combined endpoint based on "major edge dissections" (I) AND/OR "geographical mismatch" (II) [%] | Analysis of primary endpoint will be assessed by evaluation of proximal and/or distal stent end. I) Major edge dissection (MED): Major: =60 degrees of the circumference of the vessel at site of dissection and/or =3 mm in length II) Geographical mismatch (GM): Untreated plaque with a minimal lumen area <4,5mm2 within 5mm of the reference segment. In the postPCI-OCT analysis it is considered as no geographical mismatch, if: the segment of the lesion is fully covered AND the stent protrudes maximal 5mm beyond the predetermined landing zone. If one of these criteria is not fulfilled, it is considered as geographical mismatch |
Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Incidence of "major edge dissections" [%] | All secondary endpoints of OCT will be assessed by evaluation of proximal and/or distal stent end/segment. | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Incidence of "all edge dissections" (major (I) and minor (II)) [%] | (I) =60 degrees of the circumference of the vessel at site of dissection and/or =3 mm in length (II) Any visible edge dissection <60 degrees of the circumference of the vessel and < 3 mm in length | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Incidence of "geographical mismatch" [%] | see primary endpoint | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Stent expansion [%] | Defined by the MSA achieved relative to the proximal or distal reference segments. The stent length is divided into 2 equal segments (proximal and distal), and the MSA is determined in each segment. Optimal stent expansion: The MSA of the segment is =95% of the related reference lumen area Acceptable stent expansion: The MSA of the segment is =90% and <95% of the related reference lumen area Unacceptable stent expansion: The MSA of the segment is <90% of the related lumen area |
Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Inacceptable stent expansion [%] | see outcome 5 | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Incidence of "malapposition" [%] | Incompletely apposed stent struts in at least 5 consecutive OCT-frames (defined as stent struts clearly separated from the vessel wall (lumen border/plaque border) without any tissue behind the struts with a distance from the adjacent intima of =0.2 mm and not associated with any side branch). Malapposition will be further classified as: A) Major: If associated with stent underexpansion (unacceptable stent expansion as defined above) B) Minor: If not associated with significant underexpansion (optimal or acceptable stent expansion as defined above) C) Major and minor |
Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Distance between target and actual lesion coverage [mm] | Defined as the distance between target landing zone and actual landing zone of stent location (proximal and distal end). Therefore, the lesion is divided in two equal halves, so that every segment (proximal and distal) can be analyzed for itself. | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Minimal Stent Area (MSA) of target lesion [%] | Minimal lumen area covered by stent. | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Acute Luminal Gain of target lesion [mm] | Gain of Minimal Lumen Diameter (MLD) between prePCI- and postPCI-OCT | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Procedure time [min] | Time from reaching the ostium with the guide catheter until pullback of the last one. | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Total fluoroscopy time [min] | Total time required for diagnostic angiography and PCI. | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Total contrast volume [ml] | Total amount of contrast used for entire intervention (including OCT-pullbacks) | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Total stent length [mm] | Addition of each stent length which were used for target lesion | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Total number of stents | Number of stents which were used for target lesion | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Maximal stent diameter [mm] | Maximal stent diameter used for target lesion | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Complications associated with OCT-examination [%] | Complications between advancing and pullback of OCT catheter | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | Complications during hospitalization [%] | Defined as: new ACS; stent thrombosis of study culprit lesion; new unplaned coronary angiography; new revascularization (PCI/CABG); apoplex/TIA; pacemaker implantation; anaphylactic shock; contrast-induced nephropathy; bleeding; death | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours | |
Secondary | DOCE within target lesion [%] | Device-oriented composite endpoint within the target lesion. Defined as cardiovascular death, myocardial infarction OR target-lesion revascularization. This composite endpoint will be checked during a follow up after 1 and 3 months. | Time of PCI Procedure - participants will be followed for the duration of hospital stay, an expected average of 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04097912 -
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
|
||
Completed |
NCT01941355 -
Trial of Rehabilitation in Phase 1 After Coronary Artery Bypass Grafting
|
N/A | |
Active, not recruiting |
NCT03603210 -
Outcomes of Drug Coated Balloon Angioplasty, A UK Real Life Experience From 2009 to 2015
|
||
Completed |
NCT00151658 -
Sirolimus Eluting Stents in Complex Coronary Lesions (SCANDSTENT)
|
N/A | |
Recruiting |
NCT04193475 -
Machine Learning in Quantitative Stress Echocardiography
|
||
Completed |
NCT02290262 -
SheppHeartCABG - Phase One Rehabilitation After Coronary Artery Bypass Grafting
|
N/A | |
Active, not recruiting |
NCT03736018 -
Randomised Controlled Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients
|
N/A | |
Completed |
NCT02849067 -
Hemodynamic Responses of Stable Ischemic Heart Disease Patients to a Comedy Session
|
N/A | |
Recruiting |
NCT05045118 -
The Impact of Structured Patient Education Material (SPEM) in Improving Clinical and Behavioural Outcomes in Home-based Cardiac Rehabilitation Program Participants: A Pilot Study
|
N/A | |
Completed |
NCT04901767 -
Coronary Artery Endothelial Dysfunction With Drug Coated Balloons
|
||
Enrolling by invitation |
NCT03674255 -
Echocardiography: Value and Accuracy at REst and STress
|
||
Active, not recruiting |
NCT03171311 -
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
|
N/A | |
Recruiting |
NCT04768283 -
Cardiac Rehabilitation and Additional Physical Training in Elderly Patients After Acute Coronary Syndrome
|
N/A | |
Completed |
NCT02315001 -
Liraglutide to Improve corONary Haemodynamics During Exercise streSS
|
Phase 2 | |
Completed |
NCT01796353 -
Effects of a Comprehensive Sexual Rehabilitation Programme in Heart Patients
|
N/A | |
Recruiting |
NCT04061525 -
Motion and IntraCoronary Ecg Ischemia Development Study (MICE)
|
||
Recruiting |
NCT04674449 -
iCorMicA - Stratified Medicine in Angina
|
N/A | |
Active, not recruiting |
NCT02623140 -
BIOFREEDOM Stent Versus ORSIRO Stent: SORT OUT IX
|
Phase 4 | |
Completed |
NCT02053818 -
Remifentanil/Sufentanil for CABG+/-AVR Evaluated by Recovery, Cognitive Function, Haemodynamics and Biochemical Markers.
|
Phase 4 | |
Recruiting |
NCT04014140 -
iFR Guided Coronary Artery Bypass Grafting Surgery
|